Clinical trial · Observational
Retrospective Study in Sarcoma Patients
Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis®) in Sarcoma Patients
NCT03284320CI-TRIAL-00055022ReTraSarccompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin in a large cohort of German patients with soft tissue and bone sarcomas.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma of Bone | Bone Sarcoma | ALIAS | 0.90 |
| Sarcoma of Soft Tissue | Soft Tissue Sarcoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- - Progression free survival (PFS)
- timeFrame
- At the time of every treatment documentation up to the end of treatment, approximately 2 years
- measure
- - Overall survival (OS)
- timeFrame
- At the time of every treatment documentation up to the end of treatment, approximately 2 years
Secondary outcomes (1)
- measure
- CTCAE (Common Terminology Criteria for Adverse Events) 4.03
- timeFrame
- At the time of every treatment documentation up to the end of treatment, approximately 2 years
- description
- Safety Evaluation according to toxitiy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of Trabectedin in any line of therapy. * Age ≥18years at start of therapy with Trabectedin * Informed Consent * Patients already deceased may be included when the treating physician is able to determine the presumptive consent Exclusion Criteria: * No follow-up data available
References
Publications (1)
- BACKGROUNDPink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35(5):249-52. doi: 10.1159/000338342. Epub 2012 Apr 23. PMID 22868503